Somerset, NJ, USA, October 1, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, presents on October
Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is honored to
Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Gerard Blobe, MD,
Walnut Creek, CA, USA, February 14th, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, will present at the upcoming 2022 BIO CEO
Walnut Creek, CA, USA, February 7, 2022 – Vivacitas Oncology, Inc., a privately-heldbiopharmaceutical company focused on tough–to–treat cancers, is proud to present Dr. VolkerW. Stieber,
Walnut Creek, CA, USA, January 31, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, continues to grow its Neuro-Oncology Advisory Board
Walnut Creek, CA, USA, January 18, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, will be attending and presenting a poster
Walnut Creek, CA, USA, January 17, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Erkut Borazanci, MD,
WALNUT CREEK, CALIFORNIA, US, January 10, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately held clinical stage biopharmaceutical company focused on tough–to–treat cancers,
WALNUT CREEK, CALIFORNIA, US, January 3, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately held oncology company focused on tough–to–treat cancers, is pleased
1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980
2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.
3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680
4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)
5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997. https://www.jbc.org
6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org